The FDA has established a REMS program for Qsymia and any doctor that would prescribe two generics instead of the formulated Qsymia tablet is opening a huge can of worms. I'm guessing his professional insurance plan would have a stern warning against the two generic experiment.
Insurance companies are calculating cost, risk and benefit of Qysmia aided weight loss versus the diabetic costs coming from a growing number of grossly obese Americans. Give it another year and they will be lowering copays as they see the health benefits from actual patients.
The momentum in sales is growing as the public hears testimonials from the growing number of early adopters. The availability in neighborhood pharmacies will ramp things even faster.